Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 6,665 Shares of Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 6,665 shares of the business’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $47.56, for a total value of $316,987.40. Following the transaction, the insider now owns 280,793 shares of the company’s stock, valued at $13,354,515.08. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, August 7th, Carl Dambkowski sold 7,335 shares of Apogee Therapeutics stock. The shares were sold at an average price of $40.67, for a total transaction of $298,314.45.
• On Wednesday, July 3rd, Carl Dambkowski sold 5,995 shares of Apogee Therapeutics stock. The shares were sold at an average price of $37.60, for a total transaction of $225,412.00.

Apogee Therapeutics Price Performance

Shares of Apogee Therapeutics stock opened at $47.25 on Friday. The business has a fifty day simple moving average of $45.80 and a two-hundred day simple moving average of $48.98. Apogee Therapeutics, Inc. has a 1 year low of $14.19 and a 1 year high of $72.29. The company has a market capitalization of $2.76 billion, a price-to-earnings ratio of -9.00 and a beta of 2.74.

Apogee Therapeutics (NASDAQ:APGE) last posted its earnings results on Monday, August 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.60). As a group, equities analysts anticipate that Apogee Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on APGE shares. Wedbush reaffirmed an “outperform” rating and set a $87.00 price target on shares of Apogee Therapeutics in a research report on Monday, May 13th. Bank of America assumed coverage on shares of Apogee Therapeutics in a report on Friday, May 10th. They issued a “buy” rating and a $80.00 target price on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $78.50.

Institutional Investors Weigh In On Apogee Therapeutics

Several hedge funds have recently bought and sold shares of APGE. Perceptive Advisors LLC grew its position in shares of Apogee Therapeutics by 2.2% in the second quarter. Perceptive Advisors LLC now owns 2,105,636 shares of the company’s stock valued at $82,857,000 after purchasing an additional 45,241 shares during the last quarter. Driehaus Capital Management LLC boosted its stake in Apogee Therapeutics by 2.6% in the 2nd quarter. Driehaus Capital Management LLC now owns 2,117,870 shares of the company’s stock valued at $83,338,000 after purchasing an additional 54,107 shares during the period. Dark Forest Capital Management LP grew its holdings in Apogee Therapeutics by 78.3% in the 2nd quarter. Dark Forest Capital Management LP now owns 14,083 shares of the company’s stock valued at $554,000 after buying an additional 6,186 shares in the last quarter. AQR Capital Management LLC bought a new position in Apogee Therapeutics during the 2nd quarter worth $454,000. Finally, Affinity Asset Advisors LLC lifted its holdings in shares of Apogee Therapeutics by 41.2% during the second quarter. Affinity Asset Advisors LLC now owns 836,283 shares of the company’s stock worth $32,908,000 after buying an additional 244,190 shares in the last quarter. 79.04% of the stock is currently owned by institutional investors and hedge funds.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.